HGH Fragment 176-191 vs Tesamorelin: What’s the Difference?
The main difference between HGH Fragment 176-191 and Tesamorelin is mechanism: HGH Fragment 176-191 is studied for fat-loss fragment of human growth hormone — Isolated fat-burning portion of HGH. Tesamorelin is studied for visceral fat reduction research — Stabilized GHRH analog.
Fat-only GH fragment vs visceral-fat-focused GHRH analog.
Key differences between HGH Fragment 176-191 and Tesamorelin
- •Mechanism: HGH Fragment 176-191 — Isolated fat-burning portion of HGH. Tesamorelin — Stabilized GHRH analog.
- •Primary research focus: HGH Fragment 176-191 is studied for fat-loss fragment of human growth hormone; Tesamorelin is studied for visceral fat reduction research.
- •Depth of human research: HGH Fragment 176-191 — Moderate; Tesamorelin — Strong.
- •Typical study cadence cited in the literature: HGH Fragment 176-191 — Daily AM fasted, or split 2–3× daily; Tesamorelin — Daily, typically evening.
| Attribute | HGH Fragment 176-191 AOD analog, HGH Frag | Tesamorelin Stabilized GHRH analog |
|---|---|---|
| Category | Weight Loss & Metabolism | Muscle Growth & Performance |
| Best known for | Fat-loss fragment of human growth hormone | Visceral fat reduction research |
| Mechanism of action | Isolated fat-burning portion of HGH. No IGF-1 elevation, no mass gain, no insulin resistance. | Stabilized GHRH analog. Notably effective at reducing visceral (abdominal) fat. |
| Human research | Moderate | Strong |
| Animal research | Moderate | Moderate |
| Mechanistic research | Established | Established |
| Study cadence cited | Daily AM fasted, or split 2–3× daily | Daily, typically evening |
| In plain English | It is the 'fat-loss-only' slice of growth hormone, studied without the blood sugar and IGF-1 effects of full HGH. | Tesamorelin is the GH peptide with the strongest data for shrinking visceral (belly) fat specifically. |
| How it works | Believed to activate beta-3 adrenergic receptors on fat cells and stimulate lipolysis while sparing growth-related signaling. | Activates GHRH receptors, increasing GH and IGF-1 with documented preferential effects on visceral adipose tissue. |
| Researchers study | Lipolysis, body composition research, comparison with AOD9604, metabolic rate. | Visceral fat reduction, lipid metabolism, and cognitive function in older adults. |
| Internet discussion | Discussed in fat-loss and recomp circles alongside GLP-1s and AOD9604. | Discussed by people specifically targeting belly fat. |
Mechanism and research evidence, side by side
How HGH Fragment 176-191 and Tesamorelin differ at the receptor level, and how much published research currently supports each. Evidence ratings describe the depth of publicly available literature — they are not claims of safety or effectiveness.
HGH Fragment 176-191
Isolated fat-burning portion of HGH. No IGF-1 elevation, no mass gain, no insulin resistance.
- GHRH and/or ghrelin receptors in the pituitary
- Pulsatile growth hormone release
- Downstream IGF-1, body-composition and recovery endpoints
- Human research
- Moderate
- Animal research
- Moderate
- Mechanistic research
- Established
Targeted fat burning without HGH-related side effects
Tesamorelin
Stabilized GHRH analog. Notably effective at reducing visceral (abdominal) fat.
- GHRH and/or ghrelin receptors in the pituitary
- Pulsatile growth hormone release
- Downstream IGF-1, body-composition and recovery endpoints
- Human research
- Strong
- Animal research
- Moderate
- Mechanistic research
- Established
Visceral fat reduction (particularly abdominal), GH/IGF-1 increase
HGH Fragment 176-191
Fat-loss fragment of human growth hormone
It is the 'fat-loss-only' slice of growth hormone, studied without the blood sugar and IGF-1 effects of full HGH.
Believed to activate beta-3 adrenergic receptors on fat cells and stimulate lipolysis while sparing growth-related signaling.
Lipolysis, body composition research, comparison with AOD9604, metabolic rate.
Discussed in fat-loss and recomp circles alongside GLP-1s and AOD9604.
HGH Fragment 176-191 is the C-terminal fat-loss fragment of human growth hormone, studied for lipolysis without glucose or IGF-1 effects.
Tesamorelin
Visceral fat reduction research
Tesamorelin is the GH peptide with the strongest data for shrinking visceral (belly) fat specifically.
Activates GHRH receptors, increasing GH and IGF-1 with documented preferential effects on visceral adipose tissue.
Visceral fat reduction, lipid metabolism, and cognitive function in older adults.
Discussed by people specifically targeting belly fat.
Tesamorelin is the GHRH analog with strongest data for reducing visceral fat specifically.